|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common AEs should be carefully monitored in HER2-positive LABC or MBC patients treated with T-DM1 + pertuzumab ± taxane.
|
29180848 |
2017 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients enrolled were at premenopausal status and characterized by human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor positive (estrogen receptor/progesterone receptor-positive [ER/PR+]) or triple-negative (TNBC), LABC (T > 3 cm), with high-grade ductal carcinoma.
|
29744672 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
SB3 demonstrated clinical efficacy considered equivalent to that of reference trastuzumab in women with HER2-positive early or locally advanced breast cancer.
|
29796993 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive metastatic/locally advanced breast cancer (MBC/LABC).
|
30106636 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> A total of five randomized controlled studies were included in the meta-analysis, including 232 HER2-positive locally advanced breast cancer patients received the concurrent use of trastuzumab and anthracycline-based NAC.
|
30210640 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based NAC for human epidermal growth factor receptor 2 (HER2)-positive locally advanced breast cancer.
|
30310287 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study assessed H SC safety and tolerability in human epidermal growth factor receptor 2 (HER2)+ early/locally advanced breast cancer (EBC/LABC).
|
30396014 |
2018 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine estrogen, progesterone and HER2 receptors' discordances after neoadjuvant chemotherapy in patients with locally advanced breast cancer and their effects on survival.
|
30941947 |
2019 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L-T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.
|
31203575 |
2020 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neoadjuvant endocrine therapy (NAE) has been indicated to be a favorable alternate approach to downstage large or locally advanced breast cancer in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) patients, especially postmenopausal women.
|
31423426 |
2019 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Methods</i>: Patients from the GeparQuinto phase 3 trial with untreated HER2-positive operable or locally advanced breast cancer were enrolled between 7 November 2007, and 9 July 2010, and randomly assigned to receive neoadjuvant treatment with EC/docetaxel with either trastuzumab or lapatinib.
|
31443252 |
2019 |
|
Locally advanced breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This multicenter, double-blind, placebo-controlled phase 3 trial enrolled 329 women with ERBB2-positive early (T2-3, N0-1, M0) or locally advanced breast cancer (T2-3, N2 or N3, M0; T4, any N, M0) and primary tumor larger than 2 cm from March 14, 2016, to March 13, 2017.
|
31647503 |
2019 |